Transgene SA

About: Transgene SA is a company organization based out in Illkirch-Graffenstaden, France. It is known for research contribution in the topics: Antigen & Genetic enhancement. The organization has 377 authors who have published 296 publications receiving 12537 citations.

Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug

Abstract: Provided are pharmaceutical compositions for the pre-treatment of a patient in need of a drug or a pro-drug wherein said drug or pro-drug is over or under metabolized in said patient, and uses of such pharmaceutical composition.

Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation

Abstract: The present invention relates to the use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction and an antigen for the preparation of a pharmaceutical composition intended to orient the immune response toward a Th1 type response directed against said antigen, more particularly for the prevention and/or the treatment of cancer, infectious disease and allergy. Adjuvant compositions with synergic effect, vaccine compositions with synergic effect, and kits of part are also provided. Methods of treatment of individuals thereof are also provided.

Bases moléculaires de l'oncogenèse

Abstract: Les vingt-cinq dernieres annees ont permis des avancees spectaculaires dans le domaine de la recherche sur le cancer. L'ensemble de ces connaissances decrit le cancer comme une maladie faisant intervenir des changements dynamiques dans le genome cellulaire. La cancerogenese chez l'homme est un mecanisme en plusieurs etapes, dont chacune reflete des alterations genetiques aboutissant a la transformation progressive d'une cellule humaine en une cellule maligne. Durant cette transformation, les cellules tumorales detournent les circuits de regulation classiques qui gouvernent la proliferation cellulaire et l'homeostasie. Dans cette revue, nous decrirons les mecanismes moleculaires impliques dans la tumorigenese et leurs consequences.

Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells

Abstract: Described is the use of an immuno complex, which comprises at least one antibody or a reactive part thereof and at least one polynucleotide, for the preparation of a therapeutic composition for the introduction of a polynucleotide into a macropinocyte target cell wherein said immuno complex has a particle size selected between 0.5 νm and 6 νm.

Complexes for transferring substances of interest into a cell

Abstract: The present invention concerns new polar compounds, complexes and compositions comprising them, wherein said compound comprises: (i) a polar headgroup spacer, (ii) at least one hydrophobic moiety, and (iii) at least one hydrophilic polymer, and wherein said polar headgroup spacer is coupled to said hydrophobic moiety and to said hydrophilic polymer